Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100925 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL6663163 | 0.81 | RAF1 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL6658560 | 0.80 | AAK1 (0.33) | HTR2CSLC6A4 | |
| SCHEMBL6664107 | 0.79 | AKT1 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7100885 | 0.77 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7099273 | 0.77 | TBXAS1 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7099269 | 0.77 | TBXAS1 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL7098331 | 0.75 | HTR2C (0.39) | HTR2CSLC6A4 | |
| SCHEMBL5199165 | 0.73 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL618688 | 0.69 | CHRNB2 (0.59) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973743-B1 | PHARMACEUTICAL COMPOSITIONS INCORPORATING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUNDS | TARGACEPT INC (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6531606-B1 | Nicotinic compound: N-methyl-4-(3-(5-phenylpyridin)yl)-3-buten-1-amine; capable of affecting nicotinic chlorinergic receptors | TARGACEPT, INC. | 2003-03-11 | — | — | US | disclosed |
| US-6274606-B1 | ADMINISTERING COMPOUNDS SUCH AS (E)-N-METHYL-4-(3-(5-ISO PROPOXYPYRIDIN)YL)-3-BUTEN-1-AMINE TO TREAT PARKINSON'S DISEASE, TOURETTE'S SYNDROME, ATTENTION DEFICIT DISORDER, SCHIZOPHRENIA, AND ALZHEIMER'S DISEASE | TARGACEPT, INC. | 2001-08-14 | — | — | US | disclosed |
| US-5861423-A | SIDE EFFECT REDUCTION; ADMINISTERING TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; ATTENTION DEFICIT DISORDER, SCHIZOPHRENIA | TARGACEPT, INC., A CORPORATION OF DELAWARE | 1999-01-19 | — | — | US | disclosed |
| US-5811442-A | ADMINISTERING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUND IN AN AMOUNT SUFFICIENT TO SELECTIVELY BIND TO AND AFFECT NICOTINIC CHOLINERGIC RECEPTOR SUBTYPES CONTAINING BETA2 SUBUNITS | TARGACEPT, INC. | 1998-09-22 | — | — | US | disclosed |